| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Enniatin B1 targets multiple cellular processes. The compound inhibits acyl-CoA:cholesterol acyltransferase (ACAT) activity, an enzyme involved in cholesterol esterification. It decreases the activation of ERK (p44/p42), a cell proliferation kinase. Enniatin B1 also inhibits moderately TNF-alpha-induced NF-kappaB activation. The compound has been shown to induce apoptosis in several cancer cell lines. Its diverse targets contribute to its various biological activities, including antifungal, anthelmintic, insecticidal, immunomodulatory, and phytotoxic activities.
|
|---|---|
| ln Vitro |
Enniatin B1 (IC50=4.4 μM) has a sensitivity of CCF-STTG1 cells [2].
In vitro, Enniatin B1 inhibits acyl-CoA:cholesterol acyltransferase (ACAT) activity with an IC50 of 73 microM in assays using rat liver microsomes. The compound decreases the activation of ERK (p44/p42) and inhibits moderately TNF-alpha-induced NF-kappaB activation. Enniatin B1 has been shown to induce apoptosis in several cancer cell lines. It is also being used in research on drug resistance mechanisms. The compound has a variety of other biological activities such as antifungal, anthelmintic, insecticidal, immunomodulatory, and phytotoxic activity. |
| ln Vivo |
In vivo, Enniatin B1 crosses the blood-brain barrier. The compound has been used as a mycotoxin in cell viability assays. Detailed in vivo activity data for Enniatin B1 are not extensively documented in publicly available literature. As a mycotoxin with diverse bioactivities, Enniatin B1 is being studied for its toxicological effects and potential therapeutic applications. Further in vivo studies are needed to fully characterize its biological effects.
|
| Enzyme Assay |
Enzyme activity assays for Enniatin B1 are performed using rat liver microsomes as the enzyme source for ACAT activity measurement. ACAT activity is measured by monitoring the esterification of cholesterol using radiolabeled substrates. Enniatin B1 is incubated with the microsomes and substrates at varying concentrations. The reaction is stopped, and product formation is quantified by radiometric detection or HPLC. IC50 values are calculated from concentration-response curves. Nonspecific activity is determined in control reactions without inhibitor.
|
| Cell Assay |
Cellular assays for Enniatin B1 are performed using cancer cell lines to assess its effects on cell viability, proliferation, and apoptosis. Cells are cultured in appropriate media and treated with Enniatin B1 at varying concentrations for defined time periods. Cell viability and proliferation are assessed using standard assays such as MTT, CellTiter-Glo, or colony formation assays. Apoptosis is assessed by measuring caspase activation, PARP cleavage, or Annexin V staining. ERK activation and NF-kappaB activation are assessed by Western blot.
|
| Animal Protocol |
In vivo studies with Enniatin B1 are conducted in animal models to assess its toxicological effects and potential therapeutic applications. Enniatin B1 is administered via appropriate routes at defined doses and schedules. Tissue distribution, including brain penetration, is assessed. Toxicological endpoints such as organ toxicity and body weight changes are monitored. Pharmacokinetic parameters are determined from plasma samples collected at various time points.
|
| ADME/Pharmacokinetics |
Enniatin B1 has a molecular weight of 653.858 and a molecular formula of C34H59N3O9. The compound is a Fusarium mycotoxin that crosses the blood-brain barrier. Enniatin B1 inhibits ACAT activity with an IC50 of 73 microM. Detailed pharmacokinetic data for Enniatin B1 are not extensively documented in publicly available literature. The compound is soluble in DMSO and ethanol. It should be stored at -20degC.
|
| Toxicity/Toxicokinetics |
Enniatin B1 is a mycotoxin and comprehensive toxicology data are documented in the scientific literature. The compound is intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety practices should be followed when handling this compound, including the use of appropriate personal protective equipment and adherence to institutional biosafety and chemical hygiene guidelines. The compound has a purity of ≥95%.
|
| References |
|
| Additional Infomation |
According to reports, European red pine and Fusarium tricolor contain enniatin B1, and relevant data are available for reference.
Enniatin B1 is a Fusarium mycotoxin known for its diverse bioactivities. It induces apoptosis in several cancer cell lines, decreases ERK activation, inhibits ACAT activity with an IC50 of 73 microM, and inhibits TNF-alpha-induced NF-kappaB activation. Enniatin B1 crosses the blood-brain barrier and has antifungal, anthelmintic, insecticidal, immunomodulatory, and phytotoxic activities. The compound is for research purposes only. |
| Molecular Formula |
C₃₄H₅₉N₃O₉
|
|---|---|
| Molecular Weight |
653.85
|
| Exact Mass |
653.425
|
| CAS # |
19914-20-6
|
| PubChem CID |
11262300
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
833.8±65.0 °C at 760 mmHg
|
| Flash Point |
458.0±34.3 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.460
|
| LogP |
3.58
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
46
|
| Complexity |
1100
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC[C@H](C)[C@H]1C(=O)O[C@@H](C(=O)N([C@H](C(=O)O[C@@H](C(=O)N([C@H](C(=O)O[C@@H](C(=O)N1C)C(C)C)C(C)C)C)C(C)C)C(C)C)C)C(C)C
|
| InChi Key |
UQCSETXJXJTMKO-UMURLBKASA-N
|
| InChi Code |
InChI=1S/C34H59N3O9/c1-16-22(12)25-34(43)46-27(20(8)9)30(39)36(14)23(17(2)3)32(41)44-26(19(6)7)29(38)35(13)24(18(4)5)33(42)45-28(21(10)11)31(40)37(25)15/h17-28H,16H2,1-15H3/t22-,23-,24-,25-,26+,27+,28+/m0/s1
|
| Chemical Name |
(3S,6R,9S,12R,15S,18R)-3-[(2S)-butan-2-yl]-4,10,16-trimethyl-6,9,12,15,18-penta(propan-2-yl)-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5294 mL | 7.6470 mL | 15.2940 mL | |
| 5 mM | 0.3059 mL | 1.5294 mL | 3.0588 mL | |
| 10 mM | 0.1529 mL | 0.7647 mL | 1.5294 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
